CSL's Brian McNamee is expected to closely watch the move by Spanish firm Grifols to acquire Talecris and its possible effect on his company, Stephen Bartholomeusz writes in this Business Spectator commentary. The finalization of the acquisition could mean that the intravenous immunoglobulin market would be dominated by three key players with almost similar market shares, namely Baxter, CSL and Grifols, Bartholomeusz writes.

Related Summaries